Genk, Belgium
Genk, Belgium

Time filter

Source Type

Three in four patients with refractory status epilepticus treated in an intensive care unit (ICU) are still alive a year later, and half of them have recovered to baseline function, according to a new study from the University of Eastern Finland. The study was the first to show the population-based incidences for refractory and super-refractory status epilepticus and to evaluate the long-term outcome. Anne-Mari Kantanen, MD, presented the results in her doctoral thesis at the University of Eastern Finland. "The thesis addresses an extremely important area of research, in which new treatment is now being developed which hopefully will have a significant impact on outcome in this serious condition," says Professor Simon Shorvon of University College London, who assessed the thesis as the opponent. Status epilepticus (SE), a prolonged seizure, is a neurological emergency that may cause death and marked neurological deficiency. If the first and second line medications fail to terminate the seizure, the condition is called refractory status epilepticus (RSE), and if it continues beyond 24 hours after the administration of first anaesthesia, it is called super-refractory status epilepticus (SRSE). Professor Shorvon was the first to define super-refractory status epilepticus in 2011 and could only estimate the incidence at the time. Data on long-term outcomes of SE remain scarce, particularly in the cases of RSE and SRSE, and are based on small patient cohorts. The present study was the first to analyse a population-based, nationwide cohort showing the incidence and long-term - one year - outcome of intensive care unit treated and anaesthesia treated RSE and SRSE. The Finnish Intensive Care Consortium (FICC) database and medical records were used to identify adult RSE patients treated in ICU with general anaesthesia in a population-based cohort in Finland during a 3-year period from 2010 to 2012. Altogether, there were 395 incidents of RSE, of which 87 (22%) were diagnosed as SRSE. The incidence of RSE was 3.4 per 100,000 persons per year, and 0.7 per 100,000 persons per year for SRSE. The one-year mortality of all RSE and SRSE patients was 25% and 36%, respectively. Super-refractoriness, dependence on others to perform activities of daily living functions, severity of organ dysfunction at ICU admission, and higher age predicted long-term mortality. The treatment outcome was studied in more detail in Kuopio University Hospital special responsibility area with a population of 840,000 people. Nearly 50% of the ICU-treated RSE patients recovered to baseline function, whereas 30% showed new functional defects, and 20% died. The outcome was worse in older patients and in patients with progressive or fatal aetiologies. In Finland, all patients with RSE and SRSE are treated in ICUs and the cases are comprehensively documented, which made the pioneering nationwide study possible. According to Dr Kantanen, starting treatment fast and administering first aid medication already before hospitalisation following the National Current Care Guidelines are vital to treatment outcome. "When paramedics start administering first aid medication quickly and the treatment continues in a hospital under the care of an on-call physician and a neurologist, the majority of epileptic seizures can be stopped and the excessive electrical activity in the brain normalises. It is vital to analyse the patient's clinical symptoms and to perform an emergency EEG to screen out patients who need to be quickly moved to an ICU in order to stop the seizure," Dr Kantanen concludes. The results were first published in Epilepsy & Behavior, Critical Care and Epilepsy Research. The doctoral dissertation, entitled Intensive Care Treated Refractory Status Epilepticus - Incidence and Outcome in Finland 2010-2012, is available for download at http://epublications. For further information, please contact: Anne-Mari Kantanen, tel. +358407270627, anne-mari.kantanen (a) kuh.fi


News Article | May 15, 2017
Site: www.sciencedaily.com

The effects of corticosteroid treatments on pregnant women facing preterm delivery to prevent infant death and morbidity have been thought to develop gradually over days. However, a new study by researchers at Karolinska Institutet and colleagues in the European EPICE project -- coordinated by Inserm, Paris -- suggests that survival and health gains for very preterm infants may occur within hours. Hundreds of thousands of pregnant women in Europe deliver preterm every year. Even if survival nowadays is the most probable outcome, preterm birth is still one of the major causes of death in children under the age of 5. To prepare the fetus for breathing air and increase chances of survival after birth, corticosteroid treatment is given to pregnant women at risk of preterm delivery. So far, the protective effect of corticosteroids before birth has been thought to develop gradually over days. A large European study -- published in JAMA Pediatrics -- provides new knowledge, however, indicating an immediate effect. "Our study finds that antenatal (before birth) corticosteroids given to pregnant women only hours before delivery were associated with a survival advantage for their infants," says Mikael Norman, lead author, neonatologist and professor at Karolinska Institutet's Department of Clinical Science, Intervention and Technology in Stockholm, Sweden. Mikael Norman and colleagues on the EPICE (Effective Perinatal Intensive Care in Europe) research project have studied outcomes in over 4,500 very preterm infants, born at 24 to 31 weeks of gestation (excluding multiple pregnancies and severe congenital malformations) in 11 countries across Europe. In this cohort, 15 per cent of the pregnant women were not exposed to antenatal corticosteroids. 21 per cent of the unexposed infants died after birth. Infants born already 3 hours after corticosteroid administration to the mother had significantly lower mortality than those not exposed to the treatment, and corticosteroid administration 6 to 12 hours before birth was associated with halved risks of infant death. "Given the current concept of a slow effect, pregnant women at immediate risk of preterm delivery may not receive corticosteroid treatment because it is considered futile," says Dr Norman. "Also our results can provide reassurance for clinicians or parents in situations where it is not possible to wait a day or two to reach the full effect of corticosteroid treatment because of the need for action to reduce or stop ongoing morbidity in the pregnant woman and her fetus," he continues. In the study, antenatal corticosteroid treatment was also associated with a lower risk of severe neonatal morbidity such as bleedings in the brain. This reduction in the risk was associated with longer administration-to-birth intervals. "Our findings challenge current beliefs that very short exposures to antenatal steroids before delivery have no effect, and suggest that encouraging the administration of antenatal corticosteroids to pregnant women when delivery is very imminent could result in substantial survival and health gains for very preterm infants" says Jennifer Zeitlin, principal investigator of the EPICE study and researcher at Inserm (French National Institute of Health and Medical Research), Paris, France.


News Article | May 15, 2017
Site: www.eurekalert.org

The effects of corticosteroid treatments on pregnant women facing preterm delivery to prevent infant death and morbidity have been thought to develop gradually over days. However, a new study by researchers at Karolinska Institutet and colleagues in the European EPICE project - coordinated by Inserm, Paris - suggests that survival and health gains for very preterm infants may occur within hours. Hundreds of thousands of pregnant women in Europe deliver preterm every year. Even if survival nowadays is the most probable outcome, preterm birth is still one of the major causes of death in children under the age of 5. To prepare the foetus for breathing air and increase chances of survival after birth, corticosteroid treatment is given to pregnant women at risk of preterm delivery. So far, the protective effect of corticosteroids before birth has been thought to develop gradually over days. A large European study -- published in JAMA Pediatrics -- provides new knowledge, however, indicating an immediate effect. "Our study finds that antenatal (before birth) corticosteroids given to pregnant women only hours before delivery were associated with a survival advantage for their infants", says Mikael Norman, lead author, neonatologist and professor at Karolinska Institutet's Department of Clinical Science, Intervention and Technology in Stockholm, Sweden. Mikael Norman and colleagues on the EPICE (Effective Perinatal Intensive Care in Europe) research project have studied outcomes in over 4,500 very preterm infants, born at 24 to 31 weeks of gestation (excluding multiple pregnancies and severe congenital malformations) in 11 countries across Europe. In this cohort, 15 per cent of the pregnant women were not exposed to antenatal corticosteroids. 21 per cent of the unexposed infants died after birth. Infants born already 3 hours after corticosteroid administration to the mother had significantly lower mortality than those not exposed to the treatment, and corticosteroid administration 6 to 12 hours before birth was associated with halved risks of infant death. "Given the current concept of a slow effect, pregnant women at immediate risk of preterm delivery may not receive corticosteroid treatment because it is considered futile", says Dr Norman. "Also our results can provide reassurance for clinicians or parents in situations where it is not possible to wait a day or two to reach the full effect of corticosteroid treatment because of the need for action to reduce or stop ongoing morbidity in the pregnant woman and her foetus", he continues. In the study, antenatal corticosteroid treatment was also associated with a lower risk of severe neonatal morbidity such as bleedings in the brain. This reduction in the risk was associated with longer administration-to-birth intervals. "Our findings challenge current beliefs that very short exposures to antenatal steroids before delivery have no effect, and suggest that encouraging the administration of antenatal corticosteroids to pregnant women when delivery is very imminent could result in substantial survival and health gains for very preterm infants" says Jennifer Zeitlin, principal investigator of the EPICE study and researcher at Inserm (French National Institute of Health and Medical Research), Paris, France. The research received funding from the European Union's Seventh Framework Program, the French Institute of Public Health Research/Institute of Public Health and its partners, the National Research Agency through the French Equipex Program of Investments in the Future, the PremUp Foundation in France, the Polish Ministry of Science and Higher Education, regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, and Karolinska University Hospital in Sweden. Publication: "Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity in very preterm infants - results from the EPICE cohort". Mikael Norman, Aurelie Piedvache, Klaus Børch, Lene Drasbek Huusom, Anna-Karin Edstedt Bonamy, Elizabeth A. Howell, Pierre-Henri Jarreau, Rolf F. Maier, Ole Pryds, Liis Toome, Heili Varendi, Tom Weber, Emilija Wilson, Arno VanHeijst, Marina Cuttini, Jan Mazela, Henrique Barros, Patrick Van Reempts, Elizabeth Draper, Jennifer Zeitlin on behalf of the EPICE Research Group. JAMA Pediatrics, online 15 May 2017, doi:10.1001/jamapediatrics.2017.0602.


The highlighted abstracts include a study authored by clinicians from Memorial Sloan Kettering Cancer Center (MSK) analyzing the use of [TIMP-2]x[IGFBP-7] for the assessment of AKI risk in cancer patients hospitalized in the intensive care unit, It has been estimated that cancer patients represent up to 20 percent of hospital intensive care unit admissions, and up to 50 percent of these patients may experience AKI.5,6 Preexisting kidney disease, fluid and electrolyte imbalances, susceptibility to infections and use of nephrotoxic drugs are some of the factors heightening the risk of kidney injury in cancer patients.5 The development of AKI can jeopardize further cancer treatment, affect the delivery of chemotherapy,5 lead to longer length of hospital stay,7 and increase risk of permanent kidney damage4 or other complications that can undermine a patient's quality of life.8 Important Information About The NephroCheck Test The NephroCheck Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck Test System is intended to be used in patients 21 years of age or older. Astute Medical's NephroCheck Test received 510(k)-clearance through the FDA's de novo classification. The test is CE-marked and available in Europe. About Astute Medical, Inc. Astute Medical is dedicated to improving outcomes for patients with high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025. Astute Medical®, the AM logo, Astute140®, NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectualproperty. PN­­­0646 Rev A 2017/05/12 1 Bihorac A, Chawla L, Shaw A, et al. Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. Am J Respir Crit Care Med. Vol 189, Iss 8, pp 932–939, Apr 15, 2014. 2 Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25. 3 Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant. (2015) 0: 1–7doi: 10.1093/ndt/gfv130. 4 Lewington AJ, Cerdá J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013;84(3):457-467. 5 Hoste EAJ, Bagshaw SM, Bellomo R. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. (2015) 41:1411-1423 DOI 10.1007/s00134-015-3934-7. 6 Lameire et al. Critical Care (2016) 20:209 DOI 10.1186/s13054-016-1382-6. 7 Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and mortality associated with postoperative acute kidney injury. Ann Surg. 2014;00:1-8. 8 A To Z Health Guide: Acute Kidney Injury. National Kidney Foundation. Available at https://www.kidney.org/atoz/content/AcuteKidneyInjury. [Accessed May 3, 2017).] To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astute-medical-inc-highlights-ats-2017-abstracts-studying-detection-of-acute-kidney-injury-in-critically-ill-patients-300458813.html


SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” also will be published in the May 25, 2017 print issue of NEJM. “There is a major need for new treatment options for critically ill patients who do not adequately respond to available vasopressors,” stated Rinaldo Bellomo, M.D., Professor of Intensive Care Medicine at University of Melbourne and Director of Intensive Care Research at Austin Health. “In ATHOS-3, angiotensin II was shown to raise blood pressure with no increase in overall adverse events as compared to placebo in this highly treatment-resistant patient population. The effect of angiotensin II resulted in reduced use of other vasopressors. If approved, angiotensin II, in combination with other vasopressors, may allow clinicians to leverage all three major physiologic systems that regulate blood pressure.” The analysis of the primary efficacy endpoint of ATHOS-3, defined as the percentage of patients achieving a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors, was statistically significant: 23.4% of the 158 placebo-treated patients achieved the pre-specified blood pressure response, compared to 69.9% of the 163 angiotensin II-treated patients (p<0.001). In addition, a trend toward longer survival was observed for angiotensin II-treated patients (22% reduction in mortality risk through day 28; hazard ratio=0.78 [CI: 0.57, 1.07; p=0.12]). In this critically ill patient population, 91.8% of placebo-treated patients experienced at least one adverse event, compared to 87.1% of angiotensin II-treated patients, and 21.5% of placebo-treated patients discontinued treatment due to an adverse event, compared to 14.1% of angiotensin II-treated patients. The NEJM article can be found here and its Supplementary Appendix can be found here. The ATHOS-3 study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study of LJPC-501 in patients with catecholamine resistant hypotension (CRH), which is a severe form of vasodilatory shock. A total of 344 patients were randomized across nine countries, 321 of whom received study treatment and are included in the primary analysis. Patients were randomized 1:1 to receive either LJPC-501 or placebo on a background of standard-of-care vasopressors selected by the investigators. Randomized patients received their assigned treatment via continuous intravenous infusion. The primary efficacy endpoint was the percentage of patients achieving a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors. The study was conducted under a Special Protocol Assessment (SPA) agreed to with the U.S. Food and Drug Administration (FDA) in 2015. The SPA stipulates that a study of this size and design could provide sufficient safety and efficacy data and an adequate evaluation of the risk/benefit to the patients to support FDA review and consideration for marketing approval. La Jolla reported positive top-line results in February 2017. LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. LJPC-501 is being developed for the treatment of patients with CRH. LJPC-501 is the first synthetic human angiotensin II product candidate to be tested in a Phase 3 study. Catecholamine resistant hypotension (CRH) is a life-threatening syndrome in patients with vasodilatory (also known as distributive) shock (dangerously low blood pressure with adequate cardiac function) who cannot achieve target mean arterial pressure (MAP) despite adequate fluid resuscitation and treatment with currently available vasopressors (catecholamines and/or vasopressin). There are approximately 500,000 distributive shock cases in the United States per year, an estimated 200,000 of which develop CRH. More than 50% of CRH patients die within 30 days. La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla's proprietary formulation of synthetic human angiotensin II for the potential treatment of catecholamine resistant hypotension. LJPC-401 is La Jolla's proprietary formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is La Jolla's next-generation gentamicin derivative program that is focused on the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com. This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the company’s future results of operations. These statements are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors, that may cause actual results to be materially different from those anticipated by the forward-looking statements. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the company’s filings with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC’s web site www.sec.gov. These risks include, but are not limited to, risks relating to: the timing of the planned NDA submission for LJPC-501 and prospects for approval of LJPC-501 by the FDA and the other regulatory authorities; risks relating to the scope of product labels (if approved) and potential market sizes, as well as the broader commercial opportunity; the anticipated timing for regulatory actions; and the success of future development activities; potential indications for which the company’s product candidates may be developed. The company expressly disclaims any intent to update any forward-looking statements to reflect the outcome of the consequent events.


PHILADELPHIA - Penn Medicine's Pennsylvania Hospital (PAH) and the Hospital of the University of Pennsylvania (HUP) have received a three-year, $1.35 million grant from the Pennsylvania Department of Health to design an innovative and replicable program for promoting and evaluating safe sleep practices for newborns. The Philadelphia Safe Sleep Awareness for Every Well Newborn (S.A.F.E.) Program will be rolled out to hospitals, ambulatory care settings, communities, and homes and addresses the population-specific problem through nurse, parent and community education, development and dissemination of practice and education resources, and a community partnership with the Maternity Care Coalition (MCC). "In Philadelphia, 45 healthy babies die unexpectedly every year - a rate that is significantly higher than in other major cities. Research shows these tragic deaths can be prevented by following safe sleep guidelines," said Marilyn Stringer, PhD, WHCNP, FAAN, a professor of Women's Health Nursing at HUP and the principal investigator for the program. "By promoting safe sleep, and educating health care providers, parents and community members on Sudden Unexpected Infant Death (SUID) risk reduction strategies, we can help keep babies safe." "As a physician and public health leader, I am excited about using research-based strategies to more successfully educate and model safe sleep practices. I look forward to the implementation and expansion of the S.A.F.E. Program to achieve measurable results in reducing SUID," said Pennsylvania Department of Health's Deputy Secretary for Health Promotion and Disease Prevention Loren Robinson, MD, MSHP, FAAP. Development of the S.A.F.E. program comes on the heels of HUP's own program developed last year when nurses in the Intensive Care Nursery realized there was no local program aimed at improving best practices and education. That program was developed using practice guidelines from the American Academy of Pediatrics, which advises that infants sleep alone, on their back, and on a firm, flat surface with nothing else in the crib.


— The global medical beds market is projected to reach $3.41 billion by 2022 from $2.59 billion in 2017, growing at a CAGR of 5.6% during the forecast period (2017–2022). The increasing investments in healthcare infrastructural development, technological innovations in ICU beds, increasing number of beds in private hospitals, and increasing volume of chronic care patients are expected to drive the growth of the medical beds market in the coming years. On the other hand, the declining number of beds in public hospitals may limit market growth to a certain extent. Browse 85 market data tables and 30 figures spread through 145 pages and in-depth TOC on "Medical Bed Market Usage (Acute Care, Long Term Care, Psychiatric Care, Maternity), Application (Intensive Care, Non Intensive), Type (Electric Beds, Semi Electric Bed, Manual Bed), End User (Hospital, Home Care, Elderly Care) - Global Forecast to 2022" In this report, the global medical beds market is segmented on the basis of type, application, end user, usage, and region. On the basis of application, the medical beds market is segmented into two categories— intensive care and non-intensive care. The intensive care segment is expected to account for the largest share of the medical beds market. The increasing number of bariatric patients requiring intensive care is the major factor for the growth of this segment. Based on usage, the medical beds market is segmented into major four segments—acute care beds; psychiatric and bariatric care beds, long-term care beds, and other beds (maternity and rehabilitative beds). The acute care beds segment is expected to account for the largest share of the market in 2017. Increasing number of geriatric population requiring acute care beds is the major factor attributing to the growth of this market. On the basis of end user, the medical beds market is segmented into home care settings, hospitals, and elderly care facilities. The hospitals segment is expected to account for the largest share of the medical beds market in 2017. However, the home care settings segment is expected to have the fastest growth rate in the forecast period. This can be attributed to increasing government support to decrease the length of stay of patients inside hospitals. On the basis of type, medical beds market is divided into manual beds, semi-electric beds, and electric beds. The electric beds segment is expected to dominate the medical beds market in 2017.The large share as well as the high growth of this segment can primarily be attributed to the growing number of patients requiring bariatric care as well as the rising geriatric population across the globe. Order a copy of Medical Bed Market by Usage (Acute Care, Long Term Care, Psychiatric Care, Maternity), Application (Intensive Care, Non Intensive), Type (Electric Beds, Semi Electric Bed, Manual Bed), End User (Hospital, Home Care, Elderly Care) - Global Forecast to 2022 Research Report At: On the basis of region, the medical beds market North America, Europe, Asia-Pacific (APAC), and the Rest of the World (RoW). APAC is estimated to be the fastest-growing market for medical beds. This is due to the increasing geriatric population and increasing patient volume requiring chronic care in the APAC region. Other factors affecting the growth include rising elderly population, increasing obesity and overweight population, and increasing healthcare spending. New product launches was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs. Research Coverage: From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges), winning imperatives, and burning issues. The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives of governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the medical beds market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful. Reasons to buy this report: From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the medical beds market; high-growth regions; and market drivers, restraints, and opportunities. The report provides insights on the following pointers: • Market Penetration: Comprehensive information on products offered by the top players in the medical beds market • Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the medical beds market • Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for medical beds across various regions • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the medical beds market • Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the medical beds market About Us: RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.rnrmarketresearch.com/medical-bed-market-by-usage-acute-care-long-term-care-psychiatric-care-maternity-application-intensive-care-non-intensive-type-electric-beds-semi-electric-bed-manual-bed-end-user-hospital-home-care-st-to-2022-market-report.html


Researchers in all three cases employed Astute Medical's NephroCheck Test, which detects the two biomarkers and calculates an AKIRisk® Score, to determine patient risk of developing moderate to severe AKI. Several published studies have demonstrated that elevated levels of the urinary biomarkers [TIMP-2]x[IGFBP-7] can signal kidney stress indicative of AKI risk.1,2,3 Early knowledge that a patient is likely to develop AKI may prompt closer patient surveillance and enable physicians to intervene proactively in order to help mitigate or prevent permanent kidney damage or death.4 The highlighted abstracts include a study authored by clinicians from Memorial Sloan Kettering Cancer Center (MSK) analyzing the use of [TIMP-2]x[IGFBP-7] for the assessment of AKI risk in cancer patients hospitalized in the intensive care unit, It has been estimated that cancer patients represent up to 20 percent of hospital intensive care unit admissions, and up to 50 percent of these patients may experience AKI.5,6 Preexisting kidney disease, fluid and electrolyte imbalances, susceptibility to infections and use of nephrotoxic drugs are some of the factors heightening the risk of kidney injury in cancer patients.5 The development of AKI can jeopardize further cancer treatment, affect the delivery of chemotherapy,5 lead to longer length of hospital stay,7 and increase risk of permanent kidney damage4 or other complications that can undermine a patient's quality of life.8 Important Information About The NephroCheck Test The NephroCheck Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck Test System is intended to be used in patients 21 years of age or older. Astute Medical's NephroCheck Test received 510(k)-clearance through the FDA's de novo classification. The test is CE-marked and available in Europe. About Astute Medical, Inc. Astute Medical is dedicated to improving outcomes for patients with high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025. Astute Medical®, the AM logo, Astute140®, NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectualproperty. PN­­­0646 Rev A 2017/05/12 1 Bihorac A, Chawla L, Shaw A, et al. Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication. Am J Respir Crit Care Med. Vol 189, Iss 8, pp 932–939, Apr 15, 2014. 2 Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17:R25. 3 Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant. (2015) 0: 1–7doi: 10.1093/ndt/gfv130. 4 Lewington AJ, Cerdá J, Mehta RL. Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int. 2013;84(3):457-467. 5 Hoste EAJ, Bagshaw SM, Bellomo R. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. (2015) 41:1411-1423 DOI 10.1007/s00134-015-3934-7. 6 Lameire et al. Critical Care (2016) 20:209 DOI 10.1186/s13054-016-1382-6. 7 Hobson C, Ozrazgat-Baslanti T, Kuxhausen A, et al. Cost and mortality associated with postoperative acute kidney injury. Ann Surg. 2014;00:1-8. 8 A To Z Health Guide: Acute Kidney Injury. National Kidney Foundation. Available at https://www.kidney.org/atoz/content/AcuteKidneyInjury. [Accessed May 3, 2017).]


— Global Hospital Beds Market 2012- 2022 Report provides detailed analysis of market in 9 chapters with required tables and figures. Global Hospital Beds Market report classifies Hospital Beds types as Manual Hospital Beds, Electric Hospital Beds, Semi Electric Hospital Beds, By Materials, ABS Beds, Stainless Steel Beds and Alloy Bed. Applications covered in this report are Non Intensive Care and Intensive Care. This report also provides key analysis for the geographical regions like Europe, North America, China, Japan & Korea. Companies like Paramount Bed, Hill-Rom, Stryker, Linet Group, Stiegelmeyer, Joerns, Arjohuntleigh, France Bed, Pardo, Guldmann, Merivaara, Med-Mizer, Bazhou Greatwall, Sjzmanyou, Hbyangguang, Bjkangtuo, Haohan and more are profiled in this report providing information on sale, price, sales regions, products and overview. Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/529151 Table of Contents: 1 Market Overview 1.1 Objectives of Research 1.2 Market Segment 2 Industry Chain 2.1 Industry Chain Structure 2.2 Upstream 2.3 Market 3 Environmental Analysis 3.1 Policy 3.2 Economic 3.3 Technology 3.4 Market Entry 4 Major Vendors 5 Market/Vendors Distribution 5.1 Regional Distribution 5.2 Product and Application 6 Regions Market 6.1 Global 6.2 Europe 6.3 North America 6.4 China 6.5 Japan & Korea 6.6 Trade 7 Forecast 7.1 Market Trends 7.2 Segment Forecast 8 Marketing Overview 8.1 Ex-factory Price 8.2 Buyer Price 8.3 Price Factors 8.4 Marketing Channel 9 Conclusion Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/529151 For more information, please visit https://www.themarketreports.com/report/global-hospital-beds-market-research-2011-2022


News Article | April 21, 2017
Site: news.yahoo.com

Former President George H.W. Bush, who is hospitalized in Houston, is said to have an estimated net worth of $25 million as of 2013. George H.W. Bush, 92, the 41st president of United States between 1989 to 1993, has been hospitalized in Houston as he is suffering from pneumonia; however his sickness hasn't stopped the high-spirited former president to share a picture of father-son moments. George H.W. Bush tweeted a photo Thursday with a very special visitor, his son and former President George W. Bush. George H.W. Bush, who was admitted to Houston Methodist Hospital last Friday for treatment of a persistent cough, hasn't been keeping too well this year. This is the second time this year that he has been admitted to the hospital for pneumonia. There had been no improvement in his health condition and he would remain in the hospital till at least Friday, his spokesperson told CBS News. Read: George HW Bush In Stable Condition But In Intensive Care During Trump's Inauguration Earlier this month, former President Bill Clinton visited George H.W. Bush in Houston, Texas, for their annual lunch. The duo caught up on some good time as Clinton had tweeted a photo. As of 2013, George H. W. Bush, had an estimated net worth of $25 million. Bush came from a family with a tradition of public service. He graduated from Yale University, after which, he and his family moved to West Texas. He joined the oil industry and by the age of 40, he had already become a millionaire. He married Barbara Pierce George in 1945, with whom he has six children named George, Pauline, John, Neil, Marvin and Dorothy. George and Barbara Bush live in Houston, and also own the famous family compound in Kennebunkport, Maine, which is also their summer home. The home, which is is owned by the Walker’s Point Family Limited Partnership, was worth $8.4 million in 2010 and the Bush family paid $53,000 in taxes annually. The main home was built in 1920 and has 7,000 square feet, Seacoastonline reported. According to a report of the New York Times in 1988, George H. W. Bush was not that wealthy as he was thought to be because of his bearing, his privileged upbringing and his years in the oil business in Texas. Although, he was affluent with holdings worth slightly more than $2 million, he was not as rich as former President Ronald Reagan, who was likely worth almost $4 million when he became president. And Reagan's wealth was far less than the Roosevelts, the Kennedys or other politicians with huge family fortunes. Since the time Bush entered public office, his holdings did not keep pace with inflation. Most of the increase in his assets in 1980s resulted from buying and selling houses when he and his family moved. ''Making money - that hasn't been part of his life's work at all,'' Bush's brother Jonathan — an investment manager in New York City who handled George Bush's investments for a time — had told the Times. ''He had enough money to be in a public career, and that's all that mattered to him," Jonathan had said. In the recent few years, Bush has been suffering with health issues. He revealed several years ago that he suffered with a form of Parkinson's disease that deprived him from walking. He uses a wheelchair or a scooter to get around. In December 2014, he was hospitalized after experiencing shortness of breath, and the following July he fell at his home in Kennebunkport, breaking the C2 vertebrae in his neck. However, the injury did not result in any neurological problems, his spokesman had said at the time, according to CNN. Few days before President Donald Trump's inauguration ceremony, both Bush and Barbara were admitted to hospital. Bush was not expected to attend the ceremony due to health reasons. He had also sent a letter Jan. 10, apologizing for missing the ceremony and saying that he and Barbara "wish you the very best as you begin this incredible journey of leading our great country."  Trump had responded on Twitter, wishing the couple a speedy recovery and thanking them for their note, according to reports.

Loading Intensive Care collaborators
Loading Intensive Care collaborators